Σύγκριση μεθόδων

	AcroQoL: Ερωτηματολόγιο Ποιότητας Ζωής στην Ακρομεγαλία	AGHDA: Αξιολόγηση Ανεπάρκειας Αυξητικής Ορμόνης σε Ενήλικες
Πεδίο	Ενδοκρινολογία	Ενδοκρινολογία
Οικογένεια	Process / pipeline	Process / pipeline
Έτος προέλευσης	2006	2000
Δημιουργός	Markus Buchfelder, Dieter Weigel, Monica Droste, et al.	Anthony Hunt, Garry Werther, Peter Wrightson
Τύπος	Patient self-report questionnaire	Patient self-report questionnaire
Θεμελιώδης πηγή	Buchfelder, M., Weigel, D., Droste, M., et al. (2006). The quality of life of acromegaly patients is markedly impaired: Data from the German Acromegaly Registry. Eur J Endocrinol, 150(4), 541-549.	Hunt, A. E., Werther, G. A., & Wrightson, P. (2000). The utility of AGHDA in identifying GH-deficient adults. Clin Endocrinol (Oxf), 52(3), 341-346.
Εναλλακτικές ονομασίες	Acromegaly QoL, Acro-QoL	AGHDA-25
Συναφείς	3	3
Σύνοψη	AcroQoL is a disease-specific 22-item quality of life questionnaire developed to assess the multidimensional burden of acromegaly, a chronic growth hormone-secreting pituitary tumor disorder. Developed by Buchfelder and colleagues in 2006, it captures physical complications (joint/bone pain, carpal tunnel syndrome, metabolic disease), appearance-related concerns (facial changes, hand/foot enlargement), and psychological/social impacts (mood, social limitation, body image). It is the primary outcome measure for assessing quality of life in acromegaly treatment trials and clinical practice.	The AGHDA is a 25-item disease-specific quality of life questionnaire designed to assess the burden of adult growth hormone (GH) deficiency. Developed by Hunt, Werther, and colleagues in 2000, it evaluates symptoms and functional impairments directly related to GH deficiency, including fatigue, reduced muscle strength, weight gain, and psychological difficulties. The instrument is widely used in endocrinology practice and clinical trials to quantify the impact of GH replacement therapy.